Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications.

Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L.

Oxid Med Cell Longev. 2017;2017:2525967. doi: 10.1155/2017/2525967. Epub 2017 Jul 12. Review.

2.

A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III).

Biglan KM, Oakes D, Lang AE, Hauser RA, Hodgeman K, Greco B, Lowell J, Rockhill R, Shoulson I, Venuto C, Young D, Simuni T; Parkinson Study Group STEADY‐PD III Investigators.

Ann Clin Transl Neurol. 2017 May 9;4(6):360-368. doi: 10.1002/acn3.412. eCollection 2017 Jun.

3.

Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study.

Cereda E, Cilia R, Canesi M, Tesei S, Mariani CB, Zecchinelli AL, Pezzoli G.

J Neurol. 2017 Jun;264(6):1254-1263. doi: 10.1007/s00415-017-8523-y. Epub 2017 May 26. Erratum in: J Neurol. 2017 Aug 22;:.

4.

Iron Deposition Leads to Neuronal α-Synuclein Pathology by Inducing Autophagy Dysfunction.

Wan W, Jin L, Wang Z, Wang L, Fei G, Ye F, Pan X, Wang C, Zhong C.

Front Neurol. 2017 Jan 16;8:1. doi: 10.3389/fneur.2017.00001. eCollection 2017.

5.

A review of disease progression models of Parkinson's disease and applications in clinical trials.

Venuto CS, Potter NB, Dorsey ER, Kieburtz K.

Mov Disord. 2016 Jul;31(7):947-956. doi: 10.1002/mds.26644. Epub 2016 May 26. Review.

6.

Protein S-Nitrosylation as a Therapeutic Target for Neurodegenerative Diseases.

Nakamura T, Lipton SA.

Trends Pharmacol Sci. 2016 Jan;37(1):73-84. doi: 10.1016/j.tips.2015.10.002. Epub 2015 Dec 17. Review.

7.

Oxidative Stress in Neurodegenerative Diseases.

Niedzielska E, Smaga I, Gawlik M, Moniczewski A, Stankowicz P, Pera J, Filip M.

Mol Neurobiol. 2016 Aug;53(6):4094-4125. doi: 10.1007/s12035-015-9337-5. Epub 2015 Jul 22. Review.

8.

Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities.

Caldwell CC, Yao J, Brinton RD.

Neurotherapeutics. 2015 Jan;12(1):66-80. doi: 10.1007/s13311-014-0324-8. Review.

9.

Clinical applications involving CNS gene transfer.

Kantor B, McCown T, Leone P, Gray SJ.

Adv Genet. 2014;87:71-124. doi: 10.1016/B978-0-12-800149-3.00002-0. Review.

10.

Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.

Goldstein DS, Kopin IJ, Sharabi Y.

Pharmacol Ther. 2014 Dec;144(3):268-82. doi: 10.1016/j.pharmthera.2014.06.006. Epub 2014 Jun 16. Review.

11.

Bayesian hierarchical model for multiple repeated measures and survival data: an application to Parkinson's disease.

Luo S, Wang J.

Stat Med. 2014 Oct 30;33(24):4279-91. doi: 10.1002/sim.6228. Epub 2014 Jun 17.

12.

Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.

Sikorska M, Lanthier P, Miller H, Beyers M, Sodja C, Zurakowski B, Gangaraju S, Pandey S, Sandhu JK.

Neurobiol Aging. 2014 Oct;35(10):2329-46. doi: 10.1016/j.neurobiolaging.2014.03.032. Epub 2014 Apr 2.

13.

The role of oxidative stress in Parkinson's disease.

Dias V, Junn E, Mouradian MM.

J Parkinsons Dis. 2013;3(4):461-91. doi: 10.3233/JPD-130230. Review.

14.

A Bayesian approach to joint analysis of multivariate longitudinal data and parametric accelerated failure time.

Luo S.

Stat Med. 2014 Feb 20;33(4):580-94. doi: 10.1002/sim.5956. Epub 2013 Sep 6.

15.

Joint modeling of multivariate longitudinal measurements and survival data with applications to Parkinson's disease.

He B, Luo S.

Stat Methods Med Res. 2016 Aug;25(4):1346-58. doi: 10.1177/0962280213480877. Epub 2013 Apr 16.

16.

Bayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trial.

Luo S, Lawson AB, He B, Elm JJ, Tilley BC.

Stat Methods Med Res. 2016 Apr;25(2):821-37. doi: 10.1177/0962280212469358. Epub 2012 Dec 12.

17.

Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease.

Guridi J, González-Redondo R, Obeso JA.

Parkinsons Dis. 2012;2012:943159. doi: 10.1155/2012/943159. Epub 2012 Oct 17.

18.

Adjunctive therapy in Parkinson's disease: the role of rasagiline.

Gaines KD, Hinson VK.

Neuropsychiatr Dis Treat. 2012;8:285-94. doi: 10.2147/NDT.S25142. Epub 2012 Jul 2.

19.

Coenzyme Q10 deficiency in patients with Parkinson's disease.

Mischley LK, Allen J, Bradley R.

J Neurol Sci. 2012 Jul 15;318(1-2):72-5. doi: 10.1016/j.jns.2012.03.023. Epub 2012 Apr 27.

20.

Molecular chaperones in Parkinson's disease--present and future.

Ebrahimi-Fakhari D, Wahlster L, McLean PJ.

J Parkinsons Dis. 2011;1(4):299-320. Review.

Supplemental Content

Support Center